Pharmacokinetic predictions for patients with renal impairment: Focus on peptides and protein drugs

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 66-74

  Czock, David ^a   Keller, Frieder ^b   Seidling, Hanna M ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Drug dosage calculations; Peptides; Pharmacokinetics; Predictions; Proteins

Indexed keywords

AGALSIDASE ALFA; ALPHA2B INTERFERON; DENOSUMAB; DESMOPRESSIN; DIGOXIN; DROTRECOGIN; ETANERCEPT; EXENDIN 4; GOSERELIN; GROWTH HORMONE; INTERLEUKIN 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RITUXIMAB; TRIPTORELIN;

ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MOLECULAR WEIGHT; PRIORITY JOURNAL; SCIENTIFIC LITERATURE;

DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; KIDNEY; METABOLIC CLEARANCE RATE; MODELS, THEORETICAL; MOLECULAR WEIGHT; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEINS; RENAL INSUFFICIENCY;

EID: 84862118560     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04172.x     Document Type: Article

References (48)

1. Dettli L. Drug dosage in renal disease. Clin Pharmacokinet 1976; 1: 126-34.
2. Welling PG, Craig WA, Kunin CM. Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clin Pharmacol Ther 1975; 18: 45-52.
3. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab 2003; 4: 91-103.
4. Silvers A, Swenson RS, Farquhar JW, Reaven GM. Derivation of a three compartment model describing disappearance of plasma insulin-131-I in man. J Clin Invest 1969; 48: 1461-9.
5. Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron 1975; 15: 306-26.
6. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, Zampaglione N. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 1987; 27: 432-5.
7. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, Stummvoll HK, Gruenewald K. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-9.
8. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-7.
9. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.
10. Norden AG, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FW, Thakker RV, Unwin RJ, Wrong O. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int 2001; 60: 1885-92.
11. Lee JI, Zhang L, Men AY, Kenna LA, Huang SM. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin Pharmacokinet 2010; 49: 295-310.
12. Keller F, Frankewitsch T, Zellner D, Simon S, Czock D, Giehl M. Standardized structure and modular design of a pharmacokinetic database. Comput Methods Programs Biomed 1998; 55: 107-15.
13. Op den Buijsch RA, van de Plas A, Stolk LM, Christiaans MH, van Hooff JP, Undre NA, van Dieijen-Visser MP, Bekers O. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol 2007; 63: 1039-44.
14. Armendáriz Y, Pou L, Cantarell C, Lopez R, Perelló M, Capdevila L. Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 2005; 27: 431-4.
15. Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007; 22: 1920-5.
16. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003; 74: 85-94.
17. Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol 2007; 63: 41-52.
18. Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006; 45: 503-10.
19. Kawakami K, Takama H, Nakashima D, Tanaka H, Uchida E, Akizawa T. Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. Eur J Clin Pharmacol 2009; 65: 169-78.
20. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5.
21. Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, Heatherington AC, Maroni BJ. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002; 72: 546-55.
22. Takama H, Tanaka H, Nakashima D, Ogata H, Uchida E, Akizawa T, Koshikawa S. Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration. Br J Clin Pharmacol 2007; 63: 300-9.
23. CHMP Assessment Report for Prolia (Study 20040245). Available at (last accessed May 10 2011).
24. Ruzicka H, Björkman S, Lethagen S, Sterner G. Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. Pharmacol Toxicol 2003; 92: 137-42.
25. Agersø H, Seiding Larsen L, Riis A, Lövgren U, Karlsson MO, Senderovitz T. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 2004; 58: 352-8.
26. Schaumann W, Kaufmann B, Neubert P, Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 1986; 30: 527-33.
27. Renard C, Grene-Lerouge N, Beau N, Baud F, Scherrmann JM. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol 1997; 44: 135-8.
28. Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Sailstad JM, Vlasses PH, Findlay JW, Zarowitz BJ. Disposition of digoxin immune Fab in patients with kidney failure. Clin Pharmacol Ther 1993; 54: 388-94.
29. Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G III, Small DS. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72: 391-402.
30. Kindler J, Eckardt KU, Ehmer B, Jandeleit K, Kurtz A, Schreiber A, Scigalla P, Sieberth HG. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989; 4: 345-9.
31. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 1994; 5: 177-85.
32. Kawai S, Sekino H, Yamashita N, Tsuchiwata S, Liu H, Korth-Bradley JM. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol 2006; 46: 418-23.
33. Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 2005; 57: 1407-13.
34. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317-27.
35. Akizawa T, Shishido K, Koshikawa S. The effects and pharmacokinetics of rhG-CSF in patients with chronic renal failure. Artif Organs 1995; 19: 1251-7.
36. Adam HK, Barker Y, Hutchinson FG, Milsted RAV, Moore RH, Swaisland AJ. Zoladex: a one month duration LH-RH agonist. Pharm Weekbl Sci 1988; 10: 57 (Abstract).
37. García-Mayor RV, Pérez AJ, Gandara A, Andrade A, Mallo F, Casanueva FF. Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. Clin Endocrinol (Oxf) 1993; 39: 337-43.
38. Schaefer F, Baumann G, Haffner D, Faunt LM, Johnson ML, Mercado M, Ritz E, Mehls O, Veldhuis JD. Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma. J Clin Endocrinol Metab 1996; 81: 22-31.
39. Kamikawa S, Sugimoto T, Asai T, Ishii K, Kim T. Pharmacokinetic study of interleukin-2 following intravenous injection in hemodialysis patients with renal cell carcinoma. Ther Apher Dial 2008; 12: 67-71.
40. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 681-99.
41. Yang BB, Kido A, Salfi M, Swan S, Sullivan JT. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. J Clin Pharmacol 2008; 48: 1025-31.
42. Martin P, Mitra S, Farrington K, Martin NE, Modi MW. Pegylated (40kDa) interferon alpha-2a (PEGASYS) is unaffected by renal impairment. Hepatology 2000; 32 (Pt. 2 of 2): 370A (Abstract 842).
43. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109-15.
44. Gupta SK, Swan SK, Marbury T, Smith W, Schwartz S, Kolz K, Cutler DL. Multiple dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. Br J Clin Pharmacol 2007; 64: 726-32.
45. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-8.
46. Müller FO, Terblanchè J, Schall R, Smit R, Tucker T, Marais K, Groenewoud G, Porchet HC, Weiner M, Hawarden D. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol 1997; 44: 335-41.
47. Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74.
48. Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab 2009; 10: 661-91.